ANRO
Alto Neuroscience, Inc.
30.60$
+1.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| – | +76.6% | +70.3% | +104.9% | +4.0% | |
| – | +77.8% | +73.5% | +98.3% | +4.9% | |
| – | +88.1% | +70.8% | +103.8% | +4.9% | |
| – | +88.1% | +70.8% | +103.8% | +4.9% | |
| – | -68.7% | -98.5% | – | – | |
| – | – | – | – | – | |
| – | +116.3% | +77.3% | -83.5% | +28.6% | |
| – | +207.2% | +0.9% | +78.4% | +13.2% | |
| – | – | -55.8% | +596.0% | -32.8% | |
| – | +167.7% | -33.1% | +47.0% | +18.9% | |
| – | – | +4.2% | +17.2% | +59.2% | |
| – | – | – | – | -0.2% | |
| – | – | – | – | – | |
| – | +0.0% | +5.1% | -8.5% | +17.3% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.